News
GI Bleeding Lower With Apixaban vs Other DOACs in A-Fib
No substantial differences seen for other outcomes or for other direct oral anticoagulant comparisons
Your search for dabigatran returned 117 results
Uncategorized
FDA Emphasizes Special Storage and Handling Requirements for Pradaxa
The FDA is alerting healthcare providers and patients of important storage and handling requirements for Pradaxa (dabigatran etexilate mesylate capsules; Boehringer Ingelheim).
News
CHEST: New VTE Treatment Guidelines Released
The American College of Chest Physicians has released the latest evidence-based guideline with updated recommendations for appropriate treatment of patients with venous thromboembolism (VTE).
News
Pradaxa approved for stroke risk reduction
Boehringer Ingelheim announced that the FDA has approved Pradaxa (dabigatran etexilate capsules), an oral direct thrombin inhibitor, to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AFib).
News
Rates of Adverse Events Lower With Apixaban for A-Fib in Older Adults
Apixaban the only direct oral anticoagulant linked to lower adverse event rates than warfarin for patients with atrial fibrillation across frailty levels
News
GI Bleed Hospitalization Risk Linked to Oral Anticoagulant Choice, PPI Cotherapy
To compare the incidence of hospitalization for upper GI tract bleeding, researchers used US Medicare beneficiary files to identify a cohort of patients that were ≥30 years old who initiated oral anticoagulation therapy with apixaban, dabigatran, rivaroxaban, or warfarin, with or without PPI cotherapy.
News
DOACs Appear Safer Than Warfarin Across Chronic Kidney Disease Stages
Although more research is needed, data suggest that the cardioprotective effect of direct oral anticoagulants may extend to patients with advanced CKD.
Uncategorized
Evaluation of Bleeding Risk Associated with Pradaxa and Warfarin
The FDA evaluated new information about the risk of serious bleeding associated with use of dabigatran (Pradaxa; Boehringer Ingelheim) and warfarin (Coumadin, Jantoven, and generics).
AHA 2015
Study Provides Insight into Antithrombotic Tx Reintroduction After Dabigatran Reversal
Idarucizumab (Praxbind) was recently granted accelerated approval as a reversal agent for patients on Pradaxa during emergency situations.
Drug News
New Guidelines Issued for Management of Atrial Fibrillation
New recommendations have been developed for the optimum management of atrial fibrillation.
